Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits

International Journal of Pharmaceutics

Volumn 440, Issue 2, 2013, Pages 135-140

  Musumeci, Teresa ^a   Bucolo, Claudio ^a   Carbone, Claudia ^a   Pignatello, Rosario ^a   Drago, Filippo ^a   Puglisi, Giovanni ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cryoprotector; Glaucoma; IOP; Melatonin; Ocular drug delivery systems; PLGA PEG; Poly(d,l lactide co glycolide)

Indexed keywords

COPOLYMER; GLUCOSE; MELATONIN; NANOPARTICLE; POLYGLACTIN; POLYGLACTIN CO POLYETHYLENGLYCOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BIOMICROSCOPY; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; DRUG SCREENING; DRUG TOLERABILITY; FREEZE DRYING; INTRAOCULAR HYPOTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; STRUCTURE ACTIVITY RELATION; ZETA POTENTIAL;

ADMINISTRATION, OPHTHALMIC; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; INTRAOCULAR PRESSURE; LACTIC ACID; MALE; MELATONIN; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; POLYGLYCOLIC ACID; RABBITS; SURFACE PROPERTIES;

EID: 84872330873     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.10.014     Document Type: Article

References (26)

1. A. Agorastos, and C.G. Huber The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential J. Pineal Res. 50 2011 1 7
2. P. Alarma-Estrany, A. Guzman-Aranguez, F. Huete, A. Peral, R. Plourde Jr., T. Pelaez, B. Yerxa, and J. Pintor Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits J. Pharmacol. Exp. Ther. 337 2011 703 709
3. S. Alcantara-Contreras, K. Baba, and G. Tosini Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse Neurosci Lett. 494 2011 61 64
4. V. Andrés-Guerrero, P. Alarma-Estrany, I.T. Molina- Martìnez, A. Peral, R. Herrero-Vanrell, and J. Pintor Ophtalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT Exp. Eye Res. 88 2009 504 511
5. V. Andrés-Guerrero, I.T. Molina-Martínez, A. Peral, B. de Las Heras, J. Pintor, and R. Herrero-Vanrell The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analog (5-MCA-NAT) in rabbit eyes Inv. Ophthalm. Visual Sci. 52 2011 1507 2151
6. M.G. Anhorn, H.C. Mahler, and K. Langer Freeze drying of human serum albumin (HSA) nanoparticles with different excipients Int. J. Pharm. 363 2008 162 169
7. C. Bucolo, A. Maltese, F. Maugeri, B. Busà, G. Puglisi, and R. Pignatello Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene J. Pharm. Pharmacol. 56 2004 841 846
8. A. Crooke, F. Huete-Toral, A. Martínez-Águila, A. Martín-Gil, and J. Pintor Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT J. Pineal Res. 52 2012 265 270
9. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, and V. Préat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2012 505 522
10. S. Das, P.K. Suresh, and R. Desmukh Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery Nanomedicine 6 2010 318 323
11. L.C. Du Toit, V. Pillay, Y.E. Choonara, T. Govender, and T. Carmichael Ocular drug delivery-a look towards nanobioadhesives Expert Opin. Drug Deliv. 8 2011 71 94
12. C. Giannavola, C. Bucolo, A. Maltese, D. Paolino, and M.A. Vandelli Influence of preparations on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability Pharm. Res. 20 2003 584 590
13. S. Hirsjärvi, L. Peltonen, and J. Hirvonen Effect of sugars, surfactant, and tangential flow filtration on the freeze-drying AAPS PharmSciTech 10 2009 488 494
14. A.K. Jain, M. Das, N.K. Swarnakar, and S. Jain Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics Crit. Rev. Ther. Drug Carrier Syst. 28 2011 1 45
15. H. Liang, F. Brignole-Baudouin, A. Pauly, L. Riancho, and C. Baudouin Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study Adv. Ther. 28 2011 311 325
16. A. Ludwig The use of mucoadhesive polymers in ocular drug delivery Adv. Drug Deliv. Rev. 57 2005 1595 1639
17. A.A. Mahmoud, G.S. El-Feky, R. Kamel, and G.E.A. Awad Chitosan/sulfobutylether-beta-cyclodextrin nanoparticles as a potential approach for ocular drug delivery Int. J. Pharm. 413 2011 229 236
18. A. Mediero, P. Alarma-Estrany, and P. Jesús New treatments for ocular hypertension Auton. Neurosci. Basic Clin. 147 2009 14 19
19. T. Musumeci, C.A. Ventura, I. Giannone, B. Ruozi, L. Montenegro, R. Pignatello, and G. Puglisi PLA/PLGA nanoparticles for sustained release of docetaxel Int. J. Pharm. 325 2006 172 179
20. T. Musumeci, L. Vicari, C.A. Ventura, M. Gulisano, R. Pignatello, and G. Puglisi Lyoprotected nanosphere formulations for paclitaxel controlled delivery J. Nanosci. Nanotechnol. 6 2006 3118 3125
21. R. Pignatello, and G. Puglisi Nanotechnology in ophthalmic drug delivery: a survey of recent developments and patenting activity Recent Pat. Nanomed. 1 2011 42 54
22. J. Pintor, L. Martin, T. Pelaez, C.H. Hoyle, and A. Peral Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits Eur. J. Pharmacol. 416 2001 251 254
23. J. Pintor, T. Pelaez, C.H. Hoyle, and A. Peral Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor Br. J. Pharmacol. 138 2003 831 836
24. J.R. Samples, G. Krause, and A.J. Lewy Effect of melatonin on intraocular pressure Curr. Eye Res. 7 1988 649 653
25. J.B. Serle, R.F. Wang, W.M. Peterson, R. Plourde, and B.R. Yerxa Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes J. Glaucoma 13 2004 385 388
26. C. Vauthier, and K. Bouchemal Methods for the preparation and manufacture of polymeric nanoparticles Pharm. Res. 26 2009 1025 1058